Current advances in targeted therapies for metastatic gastric cancer: improving patient care
Data
2016
Autores
Aguiar, Pedro Nazareth, Jr. 
Muniz, Thiago Pimentel
Miranda, Raelson Rodrigues
Tadokoro, Hakaru
Forones, Nora Manoukian
Mostrar mais
Tipo
Revisão
Título da Revista
ISSN da Revista
Título de Volume
Resumo
In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous
therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.
therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.
Descrição
Citação
Future Oncology. London, v. 12, n. 6, p. 839-854, 2016.